Elizabeth Bhatt, who serves as President and Chief Operating Officer of Septerna, Inc. (NASDAQ: SEPN), completed a sequence of equity transactions on April 15, 2026, selling a total of 3,990 shares of the company’s common stock for roughly $97,343. The dispositions occurred across multiple trades, with execution prices spanning $23.7558 to $25.8623 per share.
On the same calendar day, Bhatt also exercised stock options to acquire 4,000 shares of Septerna common stock at an exercise price of $6.81 per share, representing a cash outlay of $27,240 to convert the options into shares.
After these moves, Bhatt’s direct ownership in Septerna stands at 174,209 shares. The insider activity comes as the stock has experienced notable gains - a 343% increase over the prior year and a 13% rise in the most recent week, according to InvestingPro data.
Analyst sentiment remains predominantly bullish. Published price targets cited by market observers span from $35 at the low end up to $60 at the high end, and InvestingPro’s internal analysis indicates the shares may still be slightly undervalued at current levels. For users seeking additional context, InvestingPro offers expanded commentary including ProTips and detailed financial metrics.
Separately, Septerna reported quarterly financial results that included a fourth-quarter loss per share of $0.24, which was smaller than the consensus expectation of a $0.72 per share loss. Revenue for the quarter totaled $24.1 million, a sum the company attributes substantially to its collaboration with Novo Nordisk.
On the clinical front, Septerna has initiated dosing in a randomized, placebo-controlled Phase 1 trial of SEP-479, a candidate for the treatment of hypoparathyroidism. The trial is designed to enroll up to 150 healthy adult volunteers to evaluate safety and efficacy.
Market research firms have reacted to these developments with mostly positive coverage. H.C. Wainwright reiterated a Buy rating and maintained a $40 price target following the start of the SEP-479 trial. Truist Securities raised its price target to $35 from $34 while retaining a Buy rating, citing progress on clinical timelines. Cantor Fitzgerald held an Overweight rating with a $60 price target and updated its financial model to incorporate the company’s recent earnings report.
The sequence of insider sale and option exercise, concurrent with clinical and financial updates, presents a compact set of near-term data points for investors tracking Septerna’s operational and market developments.